Colen, Rivka R
Rolfo, Christian
Ak, Murat
Ayoub, Mira
Ahmed, Sara
Elshafeey, Nabil
Mamindla, Priyadarshini
Zinn, Pascal O
Ng, Chaan
Vikram, Raghu
Bakas, Spyridon
Peterson, Christine B
Rodon Ahnert, Jordi
Subbiah, Vivek
Karp, Daniel D
Stephen, Bettzy
Hajjar, Joud
Naing, Aung http://orcid.org/0000-0002-4803-8513
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study (Pre-results)
https://doi.org/10.1136/jitc-2020-001532
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
https://doi.org/10.1136/jitc-2020-000665
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
https://doi.org/10.1136/jitc-2020-001752
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
https://doi.org/10.1136/jitc-2022-004822
Phase 2 study of pembrolizumab in patients with advanced rare cancers
https://doi.org/10.1136/jitc-2019-000347
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
https://doi.org/10.1136/jitc-2021-003540
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
https://doi.org/10.1007/s12325-021-01807-6
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
https://doi.org/10.1136/jitc-2022-005809
Letter to the editor from Pant<i>et al</i>
https://doi.org/10.1136/jitc-2021-003991
Funding for this research was provided by:
Hillman Cancer Center’s NCI Cancer Center Support Grant (P30CA047904)
The University of Texas MD Anderson Cancer Center Institutional Research Grant
The University of Pittsburgh Hillman Cancer Center (Startup funding)
National Institutes of Health/National Cancer Institute (P30CA016672)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.